Dose and frequency should be adjusted based on antithrombin activity, using the Innovance Antithrombin companion diagnostic test. The Food and Drug Administration (FDA) has approved Qfitlia ...

Subcutaneous Qfitlia does not replace the missing coagulation factor VIII or IX, but reduces the amount of the protein antithrombin, leading to an increase in thrombin, an enzyme critical for ...

Potentiated by concurrent treatment with antithrombin III (human) in patients with hereditary antithrombin III deficiency; reduce heparin dose.

“Clinical studies showed that by lowering antithrombin, Qfitlia was able to prophylactically reduce annualized bleeding rates by 90%. Importantly, based on its unique mechanism of ...

The antithrombin-targeted siRNA can be dosed once every two months, potentially giving it a convenience edge over anticoagulant antibodies and factor VIII and factor IX products that are dosed ...

Utilising Alnylam Pharmaceuticals’ ESC-GalNAc conjugate technology, Qfitlia prevents bleeds and helps rebalance haemostasis by lowering antithrombin, a protein that inhibits blood clotting. The ...